Meridian Bioscience Receives FDA Clearance For ImmunoCard C. difficile GDH Test
Meridian Bioscience, Inc., (NASDAQ: VIVO) today announced it has received FDA clearance for a new Clostridium difficile assay, ImmunoCard^® C. difficile GDH. This test detects the C. difficile common antigen glutamate dehydrogenase. This assay has already been successfully launched and accepted in global markets as an excellent screening option for C. difficile. The GDH common antigen is present in both toxigenic and nontoxigenic strains of C. difficile. Toxigenic strains of C. difficile are frequently associated with hospital and community-acquired diarrhea and can lead to life-threatening complications or death.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.